United Kingdom Rheumatoid
Arthritis Market is expected to grow with an impressive rate during forecast
period. Rheumatoid arthritis is a chronic autoimmune disorder where the body’s
immune system attacks its own tissues particularly at lining of the joints.
Based on the characterization by inflammation, pain, and swelling in affected
joints, rheumatoid arthritis can be classified into Seropositive Rheumatoid
Arthritis, Seronegative Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis
(JRA), Felty's Syndrome, Still's Disease, Palindromic Rheumatism, and Rheumatoid
Vasculitis. However, the most common type of rheumatoid arthritis which is
prevalent among the population of United Kingdom is Seropositive rheumatoid
arthritis. Some of the potential factors which can lead to the development of
rheumatoid arthritis include abnormal immune response, fluctuations in hormonal
levels, genetic factors, and others. Currently, in United Kingdom, there are
around 400,000 people suffering from rheumatoid arthritis. Proper treatment of
rheumatoid arthritis is necessary since it can increase the risk of developing osteoporosis,
rheumatoid nodules, infections, carpal tunnel syndrome, heart problems, lung
problems, and lymphoma. Certain medicines which are capable of decreasing the
pain and inflammation caused after rheumatoid arthritis include non-steroidal
anti-inflammatory drugs such as Ibuprofen, Naproxen, Aspirin, COX-2 inhibitors,
Corticosteroids, and Disease-modifying antirheumatic drugs (DMARDs) such as Methotrexate,
Sulfasalazine, Sulfasalazine, and others. Moreover, surgeries that can restore
the function of severely damaged joints include knee replacement and hip
replacement. United Kingdom Rheumatoid Arthritis Treatment Market is expected
to be driven by several factors in the forecast period. Increase in prevalence
of rheumatoid arthritis and complications related to it can contribute to
increased mortality rates ,in some cases. This is expected to register an
impressive growth to United Kingdom rheumatoid arthritis treatment market in
upcoming years. Furthermore, development in the healthcare system of United
Kingdom which is leading to improvement in treatment facilities for rheumatoid
arthritis is also supporting the market growth. Growing ratio of geriatric
population and emergence of osteoarthritis among them which is associated with wear
and tear on the joints over time are also expected to propel the growth of United
Kingdom Rheumatoid Arthritis Treatment Market in the forecast period.
Increasing Prevalence of
Rheumatoid Arthritis
Rheumatoid arthritis is a
systemic autoimmune disease that primarily affects the joints of wrists, knees,
ankles, shoulders, elbows, and small joints of hands and feet. Several common
symptoms that can be observed in people with rheumatoid arthritis include stiffness,
joint inflammation, fatigue, joint deformities, and systematic symptoms such as
fever, weight loss, and loss of appetite. Blood tests and imaging tests, such
as x-rays, ultrasounds, and MRI scans, are two fundamental diagnostic methods
used to identify rheumatoid arthritis in individuals. Blood tests look for
inflammation and blood proteins (antibodies) that are signs of rheumatoid
arthritis. Active diagnostic facilities in United Kingdom have increased the
confirmation rate of rheumatoid arthritis in recent years. Over ten million
people in United Kingdom are suffering from arthritis where approximately 1.5
men and 3.6 women are developing rheumatic arthritis every year per 10,000
people. Rheumatoid arthritis commonly starts between the ages of 30 and 50.
According to Rheumatology Advisor, age-standardized incidence rates ranged from
5.6 to 27.5 cases per 100,000 population in 2019, with the highest rates in the
United Kingdom, Ireland, and Sweden. Moreover, as per the report published
by UK Net, it has been concluded that around 387,000 adults have rheumatoid
arthritis in United Kingdom which is the most common form of inflammatory
arthritis. It affects around three times as many women as men. Approximately
200,000 people in UK are suffering from ankylosing spondylitis and around
177,000 are diagnosed with psoriatic arthritis. Furthermore, around 12,000
children under 16 years of age are affected with juvenile idiopathic arthritis
(JIA). Growing number of cases related to rheumatoid arthritis in
highly populated countries of United Kingdom such as England, Scotland, Wales,
and Northern Ireland are further expected to register a lucrative growth to United
Kingdom rheumatoid arthritis treatment market in the forecast period.
Development in Healthcare
Infrastructure
Growing development of United
Kingdom’s healthcare system by establishment of well-equipped rheumatology
clinics, imaging centers, infusion centers, and rehabilitation centers, are
expected to propel the growth of United Kingdom rheumatoid arthritis treatment
market in the forecast period. State-of -the- art facilities such as coil
placement, sequences, Contrast-Enhanced MRI, and Bilateral Comparison which are
helpful in accurate scanning of rheumatoid arthritis, are also contributing to
the market growth. Moreover, availability of highly qualified healthcare
professional in the region who are skilled in performing various laboratory
tests such as Rheumatoid Factor (RF), Anti-Cyclic Citrullinated Peptide
(anti-CCP) Antibodies, and Acute Phase Reactants for analysis of inflammation,
synovitis, and tendon abnormalities is also promoting the treatment for
rheumatoid arthritis in United Kingdom.
Growth in Geriatric
Population
Rise in geriatric population
across developing countries of United Kingdom and growing prevalence of
osteoarthritis which are especially associated with people during their elder
age are expected to register an impressive growth to United Kingdom rheumatoid
arthritis treatment market in the futuristic period. According to the census
results of 2021, over 11 million people which accounts for 18.6% of the total
population are aged above 65 years of age in United Kingdom. Moreover, as
per the analysis published by Statista in 2021, it has been concluded that around
12 % of total population in United Kingdom were aged between 50-49 years of
age, followed by 14% of people aged between 50-59 years, 11 % of people aged
between 60-69 years, 8% of people aged between 70-79 years of age, 5% people
aged between 80-89 years of age, and so on. Certain factors which
contribute to the development of rheumatoid arthritis in older individuals include
chronic lung diseases, cardiovascular diseases, hormonal disorders, genetic predisposition,
ageing, and others. Two distinct varieties of osteoarthritis which are highly
prevalent among geriatric population of England are hip osteoarthritis and knee
osteoarthritis. According to the report provided by Public Health England,
it has been observed that in Kensington and Chelsea, around 8,311 people aged
above 45 years are suffering from knee osteoarthritis which accounts for a male
prevalence of 13.1% followed by female prevalence of 15.9%. Moreover, in
England, a total of 5,456 people aged above 45 years were diagnosed with hip
osteoarthritis including 1,858 males (6.9%) and 3,598 females (11.9%). The treatment approach for older individuals
with rheumatoid arthritis involves physical therapy and exercise such as
aquatic therapy, occupational therapy, Transcutaneous Electrical Nerve
Stimulation (TENS) therapy, and others. Moreover, common medications which are
prescribed to older individuals for the management of rheumatoid arthritis,
include Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Disease-Modifying
Antirheumatic Drugs (DMARDs), Corticosteroids, and Biologic DMARDs such as Tumor
Necrosis Factor (TNF) inhibitors. Assistive devices and joint protection techniques
such as canes, walkers, and splints are also recommended to geriatric people to
support joint function and reduce strain on affected joints.
Recent Developments
- In August 2019, AbbVie,
a biopharmaceutical company, announced that it has received FDA approval
for the RINVOQ (upadacitinib), an oral JAK Inhibitor for the treatment of
moderate to severe rheumatoid arthritis.
- In July 2020, Mylan
announced that the FDA had approved Hurio, a biosimilar to Humira. It is a
TNF inhibitor used to treat patients with rheumatoid arthritis, juvenile
degenerative arthritis, psoriatic arthritis, reactive arthritis
spondylitis, adult Crohn's disease, gastrointestinal disorders, and
psoriatic arthritis.
- Avsola, a biosimilar
version of Remicade, a popular rheumatoid arthritis drug manufactured by
Johnson & Johnson, received US Food and Drug Administration approval
in December 2019.
Market Segmentation
United Kingdom Rheumatoid
Arthritis Treatment Market is segmented based on Treatment Type, End User, Region,
and Company. Based on treatment type, United Kingdom Rheumatoid Arthritis
Treatment Market is divided into Symptomatic Treatment, Intermediate
Corticosteroid Therapies, Stem Cell Therapies, Drugs (Disease-modifying
Anti-Rheumatic Drugs (DMARDs), Nonsteroidal Anti-inflammatory Drugs (NSAIDS),
Corticosteroids, Uric Acid Drugs, Others), and Others. On the basis of end
user, United Kingdom Rheumatoid Arthritis Treatment market is fragmented into Hospital
& clinics, Ambulatory Care Centers, and Others.
Market Players
Medtronic Ltd., 3m United
Kingdom Public Limited, ConvaTec, Inc., Smith & Nephew plc., B. Braun
Medical Ltd., Mölnlycke Health Care Limited, Novartis Pharmaceuticals UK Ltd., GlaxoSmithKline
plc., AbbVie Ltd.
|
Attribute
|
Details
|
|
Base Year
|
2022
|
|
Historic Data
|
2018 – 2021
|
|
Estimated Year
|
2023
|
|
Forecast Period
|
2024 – 2028
|
|
Quantitative Units
|
Revenue in USD Million, Volume in tons and
CAGR for 2018-2022 and 2023-2028
|
|
Report coverage
|
Revenue
forecast, Volume forecast, company share, competitive landscape, growth
factors, and trends
|
|
Segments covered
|
·
Treatment Type
·
End User
|
|
Regional scope
|
London, East
Anglia, Southwest, Southeast, Scotland, East Midlands, Yorkshire & Humberside
|
|
Key companies profiled
|
Medtronic Ltd., 3m United Kingdom
Public Limited, ConvaTec, Inc., Smith & Nephew plc., B. Braun Medical
Ltd., Mölnlycke Health Care Limited, Novartis Pharmaceuticals UK Ltd.,
GlaxoSmithKline plc., AbbVie Ltd.
|
|
Customization
scope
|
10% free report
customization with purchase. Addition or alteration to country, regional
& segment scope.
|
|
Pricing and purchase options
|
Avail customized purchase options to
meet your exact research needs. Explore purchase options
|
|
Delivery Format
|
PDF and Excel through Email (We can
also provide the editable version of the report in PPT/Word format on special
request)
|
Report Scope:
In this report, United Kingdom Rheumatoid Arthritis Treatment
Market has been segmented into following categories, in addition to the
industry trends which have also been detailed below:
·
United Kingdom Rheumatoid Arthritis Treatment Market, By Treatment Type:
o
Symptomatic
Treatment
o
Intermediate
Corticosteroid Therapies
o
Stem
Cell Therapies
o
Drugs
o
Others
- United
Kingdom Rheumatoid Arthritis Treatment Market, By End User:
o
Hospital
& Clinics
o
Ambulatory
Care Centers
o
Others
Competitive Landscape
Company Profiles: Detailed analysis of the major
companies present in United Kingdom Rheumatoid Arthritis Treatment Market.
Available Customizations:
With the given market data, TechSci Research offers
customizations according to a company’s specific needs. The following customization
options are available for the report:
Company Information
- Detailed analysis and
profiling of additional market players (up to five).
United Kingdom Rheumatoid Arthritis
Treatment Market is an upcoming report to be released soon. If you wish an
early delivery of this report or want to confirm the date of release, please
contact us at [email protected]